Atara biotherapeutics enters strategic manufacturing partnership with fujifilm

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with fujifilm diosynth biotechnologies (fdb), a subsidiary of fujifilm corporation (fujifilm) under which fujifilm will acquire atara's t-cell operations and manufa
ATRA Ratings Summary
ATRA Quant Ranking